Prescott Valley, AZ Correspondent — A waiver that can’t fill a vial is a press release, and press releases don’t lower a curve in a country without fill-finish capacity, cold chain, or a regulator who can release a lot.

Intellectual property isn’t a vial. It’s a recipe plus a factory plus a quality system, and waiving the first while the second doesn’t exist produces an ovation and the same waiting list.

Condition it on a dated manufacturing plan. So many lots, so many inspectors, so many cold-chain nodes.

Booster diplomacy should follow the same rule. Doses that can be stored, scheduled, and completed beat doses that photograph well on a tarmac and then expire.

Novi, MI Correspondent — A shop doesn’t hand a process sheet to a building that can’t hold tolerance.

The bottleneck is physical and it’s worth naming precisely: specialized lipids, glass vials, filtration membranes, bioreactor bags, and technicians who can run a sterile suite. Those are the constraint, and a declaration doesn’t move any of them.

I’d support transfer that looks like a joint venture with dates and equipment. I wouldn’t support treating a patent as the obstacle when the obstacle is a supply chain that three companies control.

Pay for the suite. That’s a capital expenditure and it can be budgeted.

Orange County, CA Correspondent — California can hold two thoughts. Share product with places that can use it, and don’t confuse a legal waiver with a factory.

The investment argument deserves a hearing on its own terms rather than as a defense of the firms. These platforms existed because capital bet on an unproven technology for a decade. The signal sent by a compulsory strip is priced into the next round of that betting, and the next pathogen is not hypothetical.

That’s not a reason to do nothing. It’s a reason to do the thing that adds capacity rather than the thing that produces a communiqué.

Condition it on absorption metrics and dated plans. Generosity is allowed to be conditional.

Bismarck, ND Correspondent — No suite, no waiver.

Doses go where they can be administered. A document isn’t a plant.

I’d add that we have a domestic version of this problem that nobody discusses. We couldn’t get shots into arms in parts of this state efficiently either, and the constraint was a nurse and a mile, not a patent.

Whatever we’re prescribing for other countries, we should notice we haven’t solved it in ours.

Jacksonville, FL Correspondent — A port sees product that can be received and product that’s a photograph.

A pledge that exceeds the receiving country’s cold chain is cargo that fails, and failed cargo is a moral position with a waste rate.

Condition both on capacity. Ship to the countries that can complete a course. Pay for the suites where we’re making a gift.

And be honest that the reason the first wave went where it went was that a handful of countries had contracts signed in advance. That’s the file, and a waiver doesn’t touch it.

Long Island, NY Correspondent — I draft transfer agreements, and an agreement that waives intellectual property into a vacuum is literature.

Condition it on enumerated capacity: lots per month, quality-release authority, cold-chain coverage, a waste-rate ceiling. Those are contract terms and terms are how a gesture becomes a program.

The legal point worth making is that the patent was never the operative barrier for these platforms. The know-how isn’t in the patent — it’s in the process, the cell lines, the analytical methods, and the people who’ve run it. That transfers through a contract and a secondment, not through a WTO decision.

Which means the waiver debate is largely symbolic in both directions, and the real question is whether anyone will pay for the technology transfer that would actually work.

Cheyenne, WY Correspondent — If they can’t bottle it, a waiver is a speech.

Doses where they can be administered. Suites if we’re paying for a gift. Not a recipe into an empty building.

Sheffield, Jamaica Correspondent — I said last year that the allocation decision was being made in advance purchase agreements while everyone agreed the international question was for later. Later has arrived, and I’d like to report what it looks like from here.

We have vaccinated a small single-digit percentage of our population. Not because we declined the doses. Because the doses were bought.

Now, on the question as asked, I largely agree with this table and I’d guess that’s unexpected. A waiver will not produce a vaccine in Jamaica. We have no fill-finish capacity, no facility that could be brought to standard in under two years, and no regulator staffed to release a biological product at scale. That is true of most of my region.

The waiver was pursued by countries that do have capacity — India, South Africa, Brazil — and for them the argument is real. For the smaller states it is a debate about a key to a door we have no building behind.

So condition it, and I would say that more strongly than the Americans here. What we need is not a legal instrument. It is doses now, delivered against a schedule we can plan a clinic around, and the honest thing is that the mechanism built for that has been badly under-supplied by the countries that promised it.

I’d ask one thing of the room. When you condition on capacity, do not let the condition become the reason. A country that cannot manufacture is not thereby a country that can wait.

Sydney, Australia Correspondent — Partners can hear the difference between a vial and a declaration.

The useful American offer in this hemisphere is product that can be absorbed, help standing up sterile capacity, and a booster plan that matches the receiving cold chain.

I’d add the regional politics, because they’re the reason to move faster. The Pacific is currently being vaccinated substantially by Chinese doses, delivered quickly and with a photograph attached, and the recipients are not weighing efficacy tables. They’re weighing who turned up.

Condition the waiver by all means. Do not let the conditioning become the excuse for arriving second, because in this region arriving second is the whole outcome.